Risks And Uncertainties That May Cause Actual Results To Differ Materially Include, Among Others, Our Capital Resources, Uncertainty Regarding The Results Of Future Testing And Development Efforts And Other Risks That Are Described In The Risk Factors Section Of Nemuss Most Recent Annual Or Quarterly Report Filed With The Securities And Exchange Commission.

In some cases, forward-looking statements can be identified by terminology including goal, focus, aims, believes, can, could, challenge, predictable, will, or the negative of these terms or other comparable terminology. no dataWe operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUSs most recent annual or quarterly report filed with the Securities and Exchange Commission. http://mejacesmith.universitypunjabi.org/2017/01/03/nevertheless-visual-improvements-were-similar-to-those-of-patients-given-conventional-treatment/Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements. ABOUT NEMUS BIOSCIENCE, INC. The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in global markets. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabinoid-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS strategy will explore the use of natural and synthetic compounds, alone or in combination. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development.

For the original version including any supplementary images or video, visit http://www.ksla.com/story/34048623/nemus-bioscience-announces-analog-of-cannabidiol-cbd-achieves-multi-chamber-ocular-penetration-in-animal-model-using-initial-ophthalmic-formulation

Leave a Reply